Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis
Board Appoints New Members, Morana Jovan-Embiricos, PhD and Owen Hughes
View HTML
Toggle Summary Radius Health to Present at BIO Business Forum(R)
Radius Health to Present at BIO Business Forum(R) CAMBRIDGE, MA--(Marketwired - Apr 18, 2013) -     Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced that President and
View HTML
Toggle Summary Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug
Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug CAMBRIDGE, MA--(Marketwire - Mar 12, 2013) - Rad ius Hea lth , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health
View HTML
Toggle Summary Radius Health to Present at Cowen & Company 33rd Annual Health Care Conference in Boston
Radius Health to Present at Cowen & Company 33rd Annual Health Care Conference in Boston CAMBRIDGE, MA--(Marketwire - Feb 26, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health
View HTML
Toggle Summary Radius Health to Present at BIO CEO & Investor in New York
Radius Health to Present at BIO CEO & Investor in New York CAMBRIDGE, MA--(Marketwire - Feb 8, 2013) - Radius Health, Inc.  ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced today that it
View HTML
Toggle Summary Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection CAMBRIDGE, MA--(Marketwire - Jan 7, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, is
View HTML
Toggle Summary Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis CAMBRIDGE, MA--(Marketwire - Jan 3, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and
View HTML
Toggle Summary Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis Cambridge, Mass., December 20, 2012 – Radius Health , Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to announce an exclusive partnership
View HTML
Toggle Summary Radius Health Withdraws Registration Statement
Radius Health Withdraws Registration Statement CAMBRIDGE, MA--(Marketwire - Nov 15, 2012) -   Radius Health , Inc. ("Radius"), announced today that it has voluntarily withdrawn its Registration Statement on Form S-1 (Registration No. 333-179397) (the "Registration Statement") that was filed on
View HTML
Toggle Summary Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting
Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting CAMBRIDGE, MA--(Marketwire - Oct 12, 2012) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of
View HTML